Edesa Biotech (NASDAQ: EDSA) reported a net loss of $2.2 million, or $0.28 per share, for the three months ended December 31 2025, compared with a $1.6 million loss, or $0.48 per share, in the same period a year earlier. Revenue for the quarter was $0.10 million, down from $0.25 million in the prior year’s quarter, reflecting the company’s pre‑revenue status. Operating expenses rose to $2.3 million, up $0.4 million from $1.9 million a year earlier; the increase was driven by $1.1 million in research and development and $1.2 million in general and administrative costs.
The larger loss was largely a result of intensified investment in the company’s vitiligo program and the manufacturing of clinical supplies for its respiratory candidate. Operating expenses grew in line with the ramp‑up of these activities, while other cost categories remained disciplined. The company’s cash and cash equivalents stood at $12.1 million, and working capital was $12.0 million, giving the company a 12‑18‑month runway at its current burn rate.
Edesa disclosed a material uncertainty that may cast substantial doubt on its ability to continue as a going concern without additional funding. The company’s revenue remains minimal, and the net loss widened as it continues to invest heavily in clinical development. Analysts had expected an EPS of –$0.28 for the quarter, and the company’s reported EPS met that consensus estimate.
Management highlighted progress in its pipeline. CEO Par Nijhawan said, "Manufacturing plans for our upcoming vitiligo study are on schedule, and we are advancing the EB06 program toward regulatory readiness and launch." CFO Peter Weiler noted, "Financial results for the first quarter reflected the continuation of trends from the preceding period, including the ramp up in activities for the company's vitiligo drug development program as well as the completion of the Phase 3 clinical study of paridiprubart." The company plans to enroll patients in its Phase 2 vitiligo study in mid‑2026 and to present Phase 3 respiratory data at upcoming scientific conferences.
Investors reacted positively to the announcement, citing the company’s progress in the EB06 program and the favorable Phase 3 data for paridiprubart as key drivers. The company’s cash position and the planned milestones provide a foundation for continued development, though the going‑concern warning underscores the need for future financing to sustain operations.
In summary, Edesa Biotech’s first‑quarter results demonstrate continued investment in its clinical pipeline, a modest revenue base, and a cash runway that supports near‑term milestones. The company’s ability to secure additional funding will be critical to maintaining its trajectory toward regulatory approval and commercialization of its lead candidates.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.